Q-omics provides the consensus-scored EIF2S3B profile across patient tissues and cancer cell-line models. EIF2S3B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, EIF2S3B is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, EIF2S3B RNA expression shows 17,753 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where EIF2S3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF2S3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF2S3B survival associations across molecular data types. EIF2S3B RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF2S3B RNA expression–survival associations across cancer types. High EIF2S3B expression shows unfavorable associations in ACC, LIHC, PAAD, LUAD and UVM, but favorable associations in KIRC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for EIF2S3B RNA expression.
This table summarizes EIF2S3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for EIF2S3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF2S3B shows higher tumor expression in COAD, LUAD, LIHC, LUSC, CHOL and READ. The COAD box plot shows higher EIF2S3B RNA expression in tumor versus normal tissue (log2 FC = +0.809, t-test p < 0.001).
This table shows molecular features associated with EIF2S3B in patient tissues and cancer cell lines. In patient samples, EIF2S3B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, EIF2S3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and PANCREAS.
